跳至主要内容
临床试验/NCT02555761
NCT02555761已完成不适用

Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea

Allergan76 个研究点 分布在 1 个国家目标入组 3,423 人开始时间: 2015年10月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Allergan
入组人数
3,423
试验地点
76
主要终点
Number of Participants with Adverse Events

研究概览

简要总结

This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with itching associated with allergic conjunctivitis.

排除标准

  • Patients with hypersensitivity to Lastacaft® or its components.

研究组 & 干预措施

Lastacaft®

One drop of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) in each eye daily as prescribed as standard of care in clinical practice.

干预措施: Alcaftadine Ophthalmic Solution 0.25% (Drug)

结局指标

主要结局

Number of Participants with Adverse Events

时间窗: 2 Weeks

次要结局

未报告次要终点

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

研究点 (76)

Loading locations...

相似试验